Lund Group

Anders H. Lund, professor, PhD
Participating group members:
Postdocs Eleonora Leucci, Lisa Frankel, Ph.D. studs Disa Tehler, Tony Bou Kheir
Address etc.:
Biotech Research and Innovation Centre (BRIC), University of Copenhagen. Ole Maaløes Vej 5, DK-2200 Copenhagen. email:

Profile of the group:

A.H. Lund joined BRIC in 2004 and became full professor in 2009. AHL directs the graduate program Molecular Mechanisms of Disease (MoMeD) and participates in the excellence Center for Epigenetics and in the FP7 network OncomiRs. AHL also manages a consortium with participation from 3 universities and 3 biotech companies focusing on the development of LNA-derived drugs against disease-related ncRNAs. AHL has obtained considerable funding from governmental and private Danish sources as well as from international sources. The group studies epigenetic gene regulation and gene regulation mediated by ncRNAs. A wide spectrum of techniques ranging from high-throughput screens over basic biochemistry and cell culture models to advanced mouse genetics are used. In general, all projects are rooted in questions related to basic biological phenomena but are studied in the context of human disease, most often cancer.


  • Gregersen LH, Jacobsen AB, Frankel LB, Wen J, Krogh A, and A. H. Lund. (2010). MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One. 2010 Jan 21;5(1):e8836.
  • Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, Klausen M, Pilpel Y, Nielsen FC, Oren M, and A. H. Lund. (2010). p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death and Differentiation 17:236-45.
  • Ørom, U. A., Nielsen, F. C. and A.H. Lund . (2008). The microRNA miR-10a stimulates global protein synthesis by increasing translation of ribosomal protein mRNAs. Molecular Cell 30: 460-471.